Marijuana Rescheduling Is Now On Hold: What Schedule III Would Mean for Hemp Buyers

Marijuana rescheduling is the most misreported story in cannabis, and the confusion is understandable: something real did happen in April, it was narrower than the headlines suggested, and a second, broader process has been running ever since. That second process hit its last briefing milestone in August and then stopped moving in September. Here is the accurate picture.

What actually happened in April

On April 28, 2026 the DEA and Acting Attorney General issued three simultaneous Federal Register actions. The one that mattered was a final rule moving two narrow categories from Schedule I to Schedule III, effective immediately and without notice-and-comment:

1. Marijuana in FDA-approved drug products
2. Marijuana subject to a state medical marijuana license

The expedited procedure was justified on Single Convention treaty grounds. At the same time, DEA issued a notice of hearing on the broader question of rescheduling all marijuana, and withdrew the prior hearing process.

The limitation people keep missing: bulk marijuana, unlicensed crops, and unapproved derivatives and extracts remain Schedule I. This was not general rescheduling. It was a carve-out for two defined categories.

What happened between June and August

The broader rescheduling hearing ran June 29 through July 15, 2026: eleven hearing days at DEA headquarters in Arlington, Virginia, before Chief Administrative Law Judge Derek C. Julius. Seven interested parties participated.

August 17, 2026 was the deadline for final post-hearing briefs, and they were filed. DEA published the full hearing transcript in September.

DEA's own brief argued for rescheduling. The agency's position is that marijuana "no longer fits the statutory requirements for Schedule I because it has a currently accepted medical use," citing more than 30,000 practitioners treating over 6 million patients across 43 jurisdictions, and arguing its abuse profile fits Schedule III.

The opposition is organized and includes states. Smart Approaches to Marijuana filed jointly with Idaho, Indiana and Nebraska. The Tennessee Bureau of Investigation filed separately, challenging the Attorney General's authority. The National Drug and Alcohol Screening Association filed on federal workplace testing grounds, and two individual filers, a physician and a pharmacist, filed as well.

September 29: the case goes on hold

On September 28, 2026, three opponents of rescheduling — DUID Victim Voices, Kenneth Finn, M.D., and the National Drug & Alcohol Screening Association — filed a motion asking ALJ Julius to admit or officially notice a Government Accountability Office report issued September 23 (GAO-26-108623), to allow supplemental briefing on it, and to recommend sending the matter back to HHS for an updated scientific and medical evaluation.

The GAO report is about federal drug scheduling procedures generally. It found that DEA has no written procedures for evaluating and scheduling substances and that FDA's written procedures are incomplete. Worth being precise about what it did not say: it did not conclude that HHS's marijuana evaluation was deficient. The movants are using a process-quality finding to argue for a remand.

On September 29 Judge Julius stayed the proceeding and ordered the government to respond by October 13, 2026; other interested parties may respond by the same date. The stay has no fixed end date. It lasts until the motion is resolved, and the order set no deadline for the recommended decision.

Practically: a decision that looked weeks away in August is now behind a procedural fight with no calendar.

What happens next, and when

The procedure from here is defined but not calendared:

1. The stay lifts when the ALJ rules on the GAO motion. The government's response was due October 13, 2026.
2. ALJ Julius issues a recommended decision. No deadline.
3. Parties have 20 days to file exceptions under 21 C.F.R. § 1316.66.
4. The DEA Administrator makes the final decision: and is not bound by the ALJ's recommendation.
5. The final order is reviewable in federal court under 21 U.S.C. § 877.

Anyone giving you a date for the outcome is guessing. There isn't one.

Why a hemp buyer should care

Schedule III would not legalize marijuana commercially. It would not create interstate cannabis commerce, it would not let dispensaries ship, and it would not make anything currently illegal legal to buy online. What it would do is change the economics on the other side of the aisle, in three ways that matter.

1. It removes 280E for state-licensed operators. Internal Revenue Code § 280E bars businesses trafficking in Schedule I or II substances from deducting ordinary business expenses. Schedule III lifts that. For dispensaries, this is an enormous margin improvement, effective tax rates in the licensed cannabis industry have run far above normal corporate rates purely because of 280E. Licensed operators with better margins can compete harder on price, and hemp's structural price advantage narrows.

2. It strengthens the case for pulling hemp into the licensed channel. Several states are already doing this. Illinois passed a law effective November 12, 2026 routing intoxicating hemp into its cannabis framework. Ohio did it in March 2026. Missouri's own version takes effect November 12, 2026. New York regulators told their legislature in February 2026 that intoxicating hemp should move into the adult-use system. Rescheduling gives that argument more force, not less.

3. It is already producing second-order effects. In August 2026, Georgia's medical cannabis commission proposed rules permitting delivery via USPS, FedEx and UPS, with officials attributing the change to the rescheduling action. That is a state proposal, not a federal mailability rule, USPS has not endorsed anything and no federal rule has changed, but it is the first concrete sign that rescheduling is being read as loosening the shipping question that has always constrained this industry.

What it does not do for hemp

To be blunt: rescheduling does not help hemp products at all. The two tracks are separate, and they are moving in opposite directions.

While marijuana moves toward Schedule III, hemp is moving toward tighter regulation. The federal hemp redefinition, total THC inclusive of THCA at 0.3%, plus a 0.4 mg per-container cap on finished products, was enacted with a November 12, 2026 effective date. H.R. 6500, signed into law on September 2, 2026, moved that to December 11, 2026 — but only for cannabinoids capable of being produced naturally, which is where THCA, hemp Delta-9 and CBD sit. Synthetic and converted cannabinoids, including most Delta-8, were left on November 12. See what the signed law actually did and whether it gets delayed again.

If both land as currently written, the result is a genuine inversion: state-licensed marijuana becomes a Schedule III substance with normal tax treatment, while hemp-derived THC products that are legal today become federally controlled. The regulated market gets easier; the unregulated one closes.

One thing DEA did not do

Worth stating because rumors circulate: DEA has taken no scheduling action against any hemp cannabinoid through October 2026. Its scheduling activity over the summer covered insomnia medications, a precursor chemical, phenethyl halides, tianeptine, and, relevant if you carry adjacent categories, 7-hydroxymitragynine and related kratom compounds, placed in Schedule I on July 6, 2026. Nothing touching hemp.

All of the current federal risk to hemp is legislative, coming from Section 781, not from DEA scheduling.

Frequently Asked Questions

Is marijuana Schedule III now?

Partly. Since April 28, 2026, marijuana in FDA-approved drug products and marijuana subject to a state medical marijuana license are Schedule III. Bulk marijuana, unlicensed crops, and unapproved derivatives and extracts remain Schedule I. The broader question is still pending.

Why was the marijuana rescheduling case paused?

On September 29, 2026 Chief ALJ Derek C. Julius stayed the proceeding after opponents of rescheduling moved to add a September 23 GAO report on federal scheduling procedures to the record and to send the matter back to HHS for an updated evaluation. The government's response was due October 13, 2026. The stay has no fixed end date.

When will the DEA decide on full rescheduling?

There is no deadline, and the case is currently stayed. Post-hearing briefs were filed August 17, 2026 and the proceeding was paused on September 29. Once it resumes, the ALJ issues a recommended decision, parties get 20 days to file exceptions, and the DEA Administrator makes the final call without being bound by the ALJ.

Does rescheduling make hemp THC products legal?

No. They are separate legal tracks. Hemp is governed by the Farm Bill definition, which narrows on December 11, 2026 for naturally occurring cannabinoids such as THCA and on November 12, 2026 for synthetic and converted ones, regardless of what happens with marijuana scheduling.

Would Schedule III let dispensaries ship cannabis to me?

Not by itself. Schedule III substances still require DEA registration and, generally, a prescription for lawful distribution, and state cannabis programs are not built on that model. A Georgia commission has proposed mail delivery for medical cannabis citing rescheduling, but no federal mailability rule has changed.

What is 280E and why does it matter?

IRC § 280E bars businesses trafficking in Schedule I or II substances from deducting normal business expenses, which has kept effective tax rates in licensed cannabis punishingly high. Schedule III removes that burden and materially improves dispensary margins.

Published August 18, 2026. Last updated October 12, 2026. General information, not legal advice. We update this page as the rescheduling process moves.